AFT Pharmaceuticals Ltd. 2025 AR2
The report highlights AFT Pharmaceuticals' financial and strategic achievements for the fiscal year ended March 31, 2025, including reaching a record revenue of $208.0 million. The company expanded its global footprint by launching Maxigesic tablets in the US and Crystaderm in China, alongside establishing new business hubs in several international markets. On the sustainability front, AFT advanced its emissions reduction plan to align with a 1.5 degree Celsius warming pathway, achieving a 12.5% reduction in combined Scope 1 and 2 emissions. Additionally, the company was recognized as 'leading' by the Australian Packaging Covenant Organisation for its waste minimisation and sustainable packaging efforts.
Company: AFT Pharmaceuticals Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2025
Type: AR2
Pages: 128
Back to company
AFT Pharmaceuticals Ltd.
Annual Report
The report highlights AFT Pharmaceuticals' financial and strategic achievements for the fiscal year ended March 31, 2025, including reaching a record revenue of $208.0 million. The company expanded its global footprint by launching Maxigesic tablets in the US and Crystaderm in China, alongside establishing new business hubs in several international markets. On the sustainability front, AFT advanced its emissions reduction plan to align with a 1.5 degree Celsius warming pathway, achieving a 12.5% reduction in combined Scope 1 and 2 emissions. Additionally, the company was recognized as 'leading' by the Australian Packaging Covenant Organisation for its waste minimisation and sustainable packaging efforts.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees